BRPI0512783A - composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto - Google Patents
composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um compostoInfo
- Publication number
- BRPI0512783A BRPI0512783A BRPI0512783-1A BRPI0512783A BRPI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A BR PI0512783 A BRPI0512783 A BR PI0512783A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- inhibiting
- treating
- treat
- inhibit
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 8
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 230000019771 cognition Effects 0.000 title abstract 2
- 238000005115 demineralization Methods 0.000 title abstract 2
- 230000002328 demineralizing effect Effects 0.000 title abstract 2
- 230000035558 fertility Effects 0.000 title abstract 2
- 230000004112 neuroprotection Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003254 radicals Chemical class 0.000 title abstract 2
- 238000001356 surgical procedure Methods 0.000 title abstract 2
- 230000003966 vascular damage Effects 0.000 title abstract 2
- 230000001457 vasomotor Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 235000012000 cholesterol Nutrition 0.000 title 1
- 239000003433 contraceptive agent Substances 0.000 title 1
- 230000002254 contraceptive effect Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 150000003626 triacylglycerols Chemical class 0.000 title 1
- 230000008602 contraction Effects 0.000 abstract 1
- 239000002834 estrogen receptor modulator Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO, MéTODOS DE TRATAR OU INIBIR OSTEOPOROSE OU INIBIR A DESMINERALIZAçãO óSSEA EM UM MAMìFERO, DE TRATAR OU INIBIR DOENçAS EM UM MAMìFERO, DE DIMINUIR O COLESTEROL, TRIGLICERìDEOS, NìVEIS DE LP(A) OU LDL OU INIBIR DANO VASCULAR EM UM MAMìFERO, DE PROVER AUMENTO DA COGNIçãO OU NEUROPROTEçãO, DE TRATAR OU INIBIR ESTADOS DOENTIOS INDUZIDOS POR RADICAL LIVRE EM UM MAMìFERO, DE TRATAR OU INIBIR SINTOMAS VASOMOTORES EM UM MAMìFERO, DE CONTRACEPçãO EM UM MAMìFERO, DE TRATAR OU INIBIR DANO DE JUNTA SECUNDáRIO A PROCEDIMENTOS ARTROSCóPICOS OU CIRúRGICOS EM UM MAMìFERO E DE TRATAR OU INIBIR FERTILIDADE EM UM MAMìFERO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçAO DE UM COMPOSTO. Esta invenção provê moduladores do receptor do estrogênio, tendo a estrutura: (1) em que R~ 1~, R~ 2~, R~ 3~, R~ 4~, Q, n, R~ 8~, R~ 9~, R~ 10~ e R~ 11~ foram definidos na especificação; ou um sal farmaceuticamente aceitável do mesmo. A invenção provê ainda métodos para a preparação e uso dos compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58451604P | 2004-07-01 | 2004-07-01 | |
| PCT/US2005/023044 WO2006007503A1 (en) | 2004-07-01 | 2005-06-29 | Tetracyclic compounds as estrogen ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512783A true BRPI0512783A (pt) | 2008-04-08 |
Family
ID=35170173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512783-1A BRPI0512783A (pt) | 2004-07-01 | 2005-06-29 | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060004087A1 (pt) |
| EP (1) | EP1761513A1 (pt) |
| JP (1) | JP2008505095A (pt) |
| CN (1) | CN1993343A (pt) |
| AU (1) | AU2005262385A1 (pt) |
| BR (1) | BRPI0512783A (pt) |
| CA (1) | CA2570518A1 (pt) |
| MX (1) | MXPA06015270A (pt) |
| WO (1) | WO2006007503A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006065968A2 (en) * | 2004-12-17 | 2006-06-22 | Wyeth | The uses of estrogen beta agonists to treat cognitive diseases |
| DE102005056890A1 (de) * | 2005-11-28 | 2007-05-31 | Institut für Umweltmedizinische Forschung gGmbH | Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut |
| AR059574A1 (es) * | 2006-02-14 | 2008-04-16 | Wyeth Corp | Formulaciones farmaceuticas acuosas de ligandos selectivos er-beta |
| WO2007128725A1 (en) * | 2006-05-03 | 2007-11-15 | Symrise Gmbh & Co. Kg | 6h-benzofuro[3,2-c] [1]benzopyran and [2] benzopyrano [4,3-b] [1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage |
| CN100389123C (zh) * | 2006-07-21 | 2008-05-21 | 中国科学院上海有机化学研究所 | 一类26-溴代-16,22-二氧代-胆甾醇化合物的合成方法 |
| EA026578B1 (ru) | 2007-01-22 | 2017-04-28 | ДЖиТиЭкс, ИНК. | Вещества, связывающие ядерные рецепторы |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| EP2048126A1 (de) * | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptanderivate als selektiv wirksame Estrogene |
| WO2009055734A1 (en) * | 2007-10-26 | 2009-04-30 | Acadia Pharmaceuticals Inc. | Condensed compounds with activity at estrogen receptors |
| ES2307462B1 (es) * | 2008-06-30 | 2009-10-14 | Fundacion Universitaria San Pablo Ceu (70%) | Derivados de naftofurano y naftotiofeno como agentes antiproliferativos del cancer de pancreas y colon. |
| US8686028B2 (en) | 2008-11-06 | 2014-04-01 | Council Of Scientific & Industrial Research | Substituted benzfurochromenes and related compounds for the prevention and treatment of bone related disorders |
| RU2554937C1 (ru) * | 2014-05-16 | 2015-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе" Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) | СПОСОБ ПОЛУЧЕНИЯ АНТРА[2,3-b]ФУРАН-3-КАРБОНОВОЙ КИСЛОТЫ |
| PE20201170A1 (es) | 2017-11-01 | 2020-10-28 | Bristol Myers Squibb Co | Compuestos biciclicos en puente como moduladores del receptor farnesoide x |
| EP4132485B1 (en) * | 2020-04-07 | 2026-02-25 | Wen Zhi LIN | Phenol for use in the treatment of coronavirus induced dyspnoea |
| CN115433200B (zh) * | 2022-08-17 | 2023-07-21 | 广州大学 | 含苯并二氢吡喃-4-酮结构的四环化合物、合成方法及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4704400A (en) * | 1986-06-24 | 1987-11-03 | Merck & Co., Inc. | Medicarpin derivatives and analogs |
| US5147880A (en) * | 1991-07-22 | 1992-09-15 | Eli Lilly And Company | Benzo[a]fluorene compounds |
| JP3050667B2 (ja) * | 1991-09-18 | 2000-06-12 | ライオン株式会社 | 抗男性ホルモン剤 |
| US5399558A (en) * | 1993-11-24 | 1995-03-21 | Pathogenesis Corporation | Isoflavonoid antibacterial compounds, compositions and use |
| US5721371A (en) * | 1995-12-18 | 1998-02-24 | Iowa State University Research Foundation, Inc. | Synthesis of substituted pterocarpans |
| US5998402A (en) * | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US6589980B2 (en) * | 2001-05-17 | 2003-07-08 | Wyeth | Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TW200301107A (en) * | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
| US6884814B2 (en) * | 2001-12-13 | 2005-04-26 | Wyeth | Phenyl benzisoxazoles as estrogenic agents |
| US6960607B2 (en) * | 2001-12-13 | 2005-11-01 | Wyeth | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents |
| US6914074B2 (en) * | 2001-12-13 | 2005-07-05 | Wyeth | Substituted phenyl naphthalenes as estrogenic agents |
| US6774248B2 (en) * | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| CN101052641A (zh) * | 2004-09-07 | 2007-10-10 | 惠氏公司 | 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途 |
-
2005
- 2005-06-29 US US11/170,017 patent/US20060004087A1/en not_active Abandoned
- 2005-06-29 JP JP2007519381A patent/JP2008505095A/ja active Pending
- 2005-06-29 EP EP05788764A patent/EP1761513A1/en not_active Withdrawn
- 2005-06-29 AU AU2005262385A patent/AU2005262385A1/en not_active Withdrawn
- 2005-06-29 BR BRPI0512783-1A patent/BRPI0512783A/pt not_active IP Right Cessation
- 2005-06-29 WO PCT/US2005/023044 patent/WO2006007503A1/en not_active Ceased
- 2005-06-29 MX MXPA06015270A patent/MXPA06015270A/es unknown
- 2005-06-29 CN CNA2005800224317A patent/CN1993343A/zh not_active Withdrawn
- 2005-06-29 CA CA002570518A patent/CA2570518A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060004087A1 (en) | 2006-01-05 |
| AU2005262385A1 (en) | 2006-01-19 |
| JP2008505095A (ja) | 2008-02-21 |
| WO2006007503A1 (en) | 2006-01-19 |
| CN1993343A (zh) | 2007-07-04 |
| EP1761513A1 (en) | 2007-03-14 |
| CA2570518A1 (en) | 2006-01-19 |
| MXPA06015270A (es) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512783A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de tratar ou inibir osteoporose ou inibir a desmineralização óssea em um mamìfero, de tratar ou inibir doenças em um mamìfero, de diminuir o colesterol, triglicerìdeos, nìveis de lp (a) ou ldl ou inibir dano vascular em um mamìfero, de prover aumento da cognição ou neuroproteção, de tratar ou inibir estados doentios induzidos por radical livre em um mamìfero, de tratar ou inibir sintomas vasomotores em um mamìfero, de contracepção em um mamìfero, de tratar ou inibir dano de junta secundário a procedimentos artroscópicos ou cirúrgicos em um mamìfero e de tratar ou inibir fertilidade em um mamìfero, composição farmacêutica, e, processo para a preparação de um composto | |
| Orbay et al. | Multicenter trial of an internal joint stabilizer for the elbow | |
| Leigh et al. | Radial head reconstruction versus replacement in the treatment of terrible triad injuries of the elbow | |
| Amir et al. | Distal humerus fractures: a review of current therapy concepts | |
| Christensen et al. | Revision of the stiff total knee arthroplasty | |
| GRANOWITZ et al. | The pathogenesis and long-term end results of pigmented villonodular synovitis | |
| BR0112364A (pt) | Combinações de bisfosfonatos, agentes estrogênicos e opcionalmente estrogênios | |
| BR0113200A (pt) | Combinação terapêutica | |
| BRPI0514628A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou inibir doenças, métodos para baixar os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl; ou inibir avaria da parede vascular, para prover aumento de cognição ou neuroproteção; para tratar ou inibir estados doentios induzidos por radical livre, condições, e inchação ou erosão de junta; ou tratar ou inibir avaria de junta secundária a procedimentos artroscópicos ou cirúrgicos, e, composição farmacêutica | |
| Howie et al. | Cemented total hip arthroplasty with subtrochanteric osteotomy in dysplastic hips | |
| BR0109983A (pt) | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes | |
| Valenti et al. | Shoulder hemiarthroplasty for proximal humeral fractures: analysis of clinical and radiographic outcomes at midterm follow-up: a series of 51 patients | |
| BR0115291A (pt) | Derivados de 2-fenilaminoimidazolina fenil cetona substituìdos como antagonistas de ip | |
| Lee et al. | Lateral fixation of AO type-B2 ankle fractures in the elderly: the Knowles pin versus the plate | |
| Salazar et al. | Unique indications for internal joint stabilizer for elbow instability | |
| BR0010802A (pt) | Antagonistas de receptor il-8 | |
| Bach et al. | Disability can be avoided after open fractures in Africa—results from Malawi | |
| Nagata et al. | The management of secondary frozen shoulder after anterior shoulder dislocation–the results of manipulation under anaesthesia and injection | |
| Bennett et al. | Total elbow arthroplasty: surgical technique | |
| Marcuzzi et al. | Chronic transscaphoid, transcapitate perilunate fracture dislocation of the wrist: Fenton's syndrome | |
| BR0314700A (pt) | Derivados que compreendem esteróis e/ou estanóis e classes especìficas de agentes antiinflamatórios e seu uso no tratamento ou prevenção de doença cardiovascular | |
| Guo et al. | Polylactide pins can effectively fix severely comminuted and unsalvageable radial head fracture: a retrospective study of 40 patients | |
| Späth et al. | Complications and efficacy of transsternal thymectomy in myasthenia gravis | |
| BR9913348A (pt) | Tratamento dos distúrbios da ansiedade | |
| BR0212824A (pt) | Composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |